Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin Pretransplant

Título del documento: Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin Pretransplant
Revue: Annals of hepatology
Base de datos: PERIÓDICA
Número de sistema: 000407815
ISSN: 1665-2681
Autores: 1
Instituciones: 1Vancouver General Hospital, Division of Gastroenterology, Vancouver, Columbia Británica. Canadá
2Indiana University, School of Medicine, Indianapolis, Indiana. Estados Unidos de América
3King’s College Hospital Foundation Trust, Institute of Liver Studies, Londres. Reino Unido
4Universite Paris-Est Creteil, Centre Hospitalier Universitaire Henri-Mondor, Val de Marne, París. Francia
5Universite Paris Diderot, Beaujon Hospital, Clichy, París. Francia
6Medical University of Vienna, Department of Gastroenterology and Hepatology, Viena. Austria
7University of Toronto, Toronto General Hospital, Toronto, Ontario. Canadá
8Universite de Montreal, Hospital Saint Luc, Montreal, Quebec. Canadá
9Mayo Clinic, Division of Gastroenterology and Hepatology, Phoenix, Arizona. Estados Unidos de América
10Georgetown University, Division of Infectious Diseases, Washington, Distrito de Columbia. Estados Unidos de América
11Weill Cornell Medical College, Division of Gastroenterology and Hepatology, Nueva York. Estados Unidos de América
12Universite Catholique de Louvain, Lovaina. Bélgica
13Gilead Sciences, Inc., Foster City, California. Estados Unidos de América
14University of California, Division of Gastroenterology and Hepatology, San Francisco, California. Estados Unidos de América
15Universita di Torino, Dipartimento di Gastroenterologia, Turín, Piemonte. Italia
16University Hospital Zurich, Department for Gastroenterology and Hepatology, Zurich. Suiza
Periodo: May-Jun
Volumen: 16
Número: 3
Paginación: 375-381
País: México
Idioma: Inglés
Tipo de documento: Artículo
Enfoque: Analítico, descriptivo
Resumen en inglés Recurrence of HCV infection in patients with chronic hepatitis C virus (HCV) at the time of liver transplantation is nearly universal and reduces the likelihood of graft and patient survival. Materials and methods. Materials and methods. We evaluated outcomes of 17 Materials and methods. patients (16 with HCV genotype 1 and 1 with genotype 4) who received up to 12 or 24 weeks of ledipasvir/sofosbuvir plus ribavirin prior to or up to the time of liver transplant in the SOLAR-1 and SOLAR-2 trials. In all patients, HCV RNA was < 15 IU/mL prior to transplant. At screening, 6 patients were Child-Pugh-Turcotte (CPT) class B and 11 were CPT class C. Seven patients underwent transplant prior to completing assigned treatment, with 4 treated for < 12 weeks. The primary endpoint was posttransplant virologic response 12 weeks after transplant (pTVR12) in patients with HCV RNA < 15 IU/mL at their last measurement prior to transplant. Results. Results. Results. Overall, 94% (16/17) achieved pTVR12. All who achieved pTVR12 received at least 11 weeks of treatment. The single patient who did not achieve pTVR12 discontinued study drug on day 21 and underwent liver transplant the following day. The patient had HCV RNA < 15 IU/mL at post-transplant week 2 but died 15 days post-transplant because of multi-organ failure and septic shock. Conclusion. Conclusion. Conclusion. Among a small population of HCV patients with decompensated cirrhosis, virologic response to ledipasvir / sofosbuvir plus ribavirin prior to liver transplantation was maintained after transplantation, even if treatment was stopped early. Administration of ledipasvir / sofosbuvir plus ribavirin before liver transplant can prevent post-transplant HCV recurrence
Disciplinas: Medicina
Palabras clave: Gastroenterología,
Hepatitis crónica,
Hepatitis C,
Virus de la hepatitis C,
Trasplante de hígado,
Terapia antiviral,
Keyword: Medicine,
Chronic hepatitis,
Hepatitis C,
Hepatitis C virus,
Liver transplantation,
Antiviral therapy,
Texte intégral: Texto completo (Ver PDF)